Florian Kron

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 13

Top Topics

Molecularly Imprinted

Diffuse Large B Cell Lymphoma

Top Venues

Cost effectiveness and resource allocation : C/E

European journal of haematology

This page only lists publications with an associated author ORCID identifier.

Publications

Melina Sophie Kurte, Ann-Cathrine Siefen, Florian Jakobs, Tabea Poos, Julia von Tresckow, Bastian von Tresckow, Hans Christian Reinhardt, Florian Kron
Time-dependent cost comparison and health economic impact analysis of second-line interventions for transplant-ineligible patients with relapsed or refractory diffuse large B cell lymphoma. European journal of haematology 113 (3) (2024)
Ann-Cathrine Siefen, Melina Sophie Kurte, Anna Marie Bauer, Oliver Andreas Cornely, Sebastian M Wingen-Heimann, Florian Kron
A Retrospective Budget Impact Analysis of Fidaxomicin Treatment for Clostridioides difficile Infections (CDI) in Germany. Expert review of pharmacoeconomics & outcomes research (2024)
Amelie Wickmann, Melina Sophie Kurte, Julia Jeck, Luisa Camacho, Dennis Klinkhammer, Florian Kron, Robert Dengler
Cost-benefit evaluation of advanced therapy lines in metastatic triple-negative breast cancer in Germany. Cost effectiveness and resource allocation : C/E 22 (1) (2024)
Amelie Wickmann, Melina Sophie Kurte, Julia Jeck, Luisa Camacho, Dennis Klinkhammer, Florian Kron, Robert Dengler
Cost-benefit evaluation of advanced therapy lines in metastatic triple-negative breast cancer in Germany. Cost effectiveness and resource allocation : C/E 22 (1) (2024)
Amelie Wickmann, Melina Sophie Kurte, Julia Jeck, Luisa Camacho, Dennis Klinkhammer, Florian Kron, Robert Dengler
Cost-benefit evaluation of advanced therapy lines in metastatic triple-negative breast cancer in Germany. Cost effectiveness and resource allocation : C/E 22 (1) (2024)
Melina Sophie Kurte, Ann-Cathrine Siefen, Florian Jakobs, Tabea Poos, Julia von Tresckow, Bastian von Tresckow, Hans Christian Reinhardt, Florian Kron
Time-dependent cost comparison and health economic impact analysis of second-line interventions for transplant-ineligible patients with relapsed or refractory diffuse large B cell lymphoma. European journal of haematology (2024)
Amelie Wickmann, Melina Sophie Kurte, Julia Jeck, Luisa Camacho, Dennis Klinkhammer, Florian Kron, Robert Dengler
Cost-benefit evaluation of advanced therapy lines in metastatic triple-negative breast cancer in Germany. Cost effectiveness and resource allocation : C/E 22 (1) (2024)
Julia Jeck, Sebastian M Wingen-Heimann, Florian Jakobs, Anna Kron, Jennifer Franz, Oliver Andreas Cornely, Florian Kron
Health economic analysis of patients treated with isavuconazole in a German comprehensive cancer centre. Mycoses (2023)
Ann-Cathrine Siefen, Leonie Eilers, Christoph T Baltin, Florian Kron
Cost Comparison of Treatment Alternatives for Pleural Effusion and Ascites from a Payer Perspective: Are There Cost Savings from Indwelling Catheters? Journal of palliative medicine (2023)
Melina Sophie Kurte, Ann-Cathrine Siefen, Florian Jakobs, Bastian von Tresckow, Hans Christian Reinhardt, Florian Kron
Cost-effectiveness analysis of transplant-ineligible relapsed or refractory diffuse large B-cell lymphoma treatment options-Experience of the efficiency frontier approach. European journal of haematology (2023)
Julia Jeck, Florian Jakobs, Anna Kron, Jennifer Franz, Oliver A Cornely, Florian Kron
A cost of illness study of COVID-19 patients and retrospective modelling of potential cost savings when administering remdesivir during the pandemic "first wave" in a German tertiary care hospital. Infection (2021)
Julia Jeck, Sebastian M Wingen-Heimann, Christian Thielscher, Anna Kron, Jennifer Bonn, Florian Jakobs, Santiago Grau, David A Enoch, Christianne Micallef, Oliver Andreas Cornely, Florian Kron
Reimbursement of innovative pharmaceuticals in English and Spanish hospitals-The example of isavuconazole. Mycoses 64 (10) (2021)
Florian Kron, Sebastian M Wingen-Heimann, Julia Jeck, Carlo Lazzaro, Oliver Andreas Cornely, Christian Thielscher
Principal-agent theory-based cost and reimbursement structures of isavuconazole treatment in German hospitals. Mycoses 64 (1) (2020)